How Low Does Merck Need To Go? FDA Safety Concerns May Cut Suvorexant’s Dosing
This article was originally published in The Pink Sheet Daily
FDA will ask an advisory committee whether Merck’s insomnia drug should employ the tiered dosing schedule proposed for the elderly and non-responders, but the agency seems inclined towards a dose even lower that the ones that were used in Phase III.
You may also be interested in...
The Peripheral and Central Nervous System Drugs Advisory Committee’s May 22 review of the first-in-class insomnia drug will include data from two studies assessing the compound’s residual effects on next-day driving.
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Merck reports second quarter earnings, looking past the patent expiration of Singulair to the drugs it icurrently is developing to replace the revenues it is expected to lose.